Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G. Richardson, Yen Charles, Albert Oriol et al.|The Lancet Oncology|2019Cited by 383
Time to redefine MyelomaGuy Pratt, Jenny Bird, Stella Bowcock et al.|British Journal of Haematology|2015Cited by 17
A follow‐up survey of knowledge, attitudes and practices surrounding blood donation in Trinidad and TobagoKenneth S. Charles, Andrew Chantry, Angel A Justiz-Vaillant et al.|ISBT Science Series|2017Cited by 9